Veracyte, Inc. (VCYT)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
$24.00-54.30%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
QuarterlyIQ Insights · VCYT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -48.5% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 11.6% |
Growth built into the price is above our model estimate.
The price assumes 60.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 18 industry peers · Company calendar date is not available
VCYT — officer change
Dated 2026-06-11
The excerpt is incomplete and does not provide sufficient details to determine the nature of the event.
Why it matters: Prosigna LDT is a new product, but the company has not yet reported its sales. Early uptake would support its growth case.
Supportive ifVeracyte reports Prosigna LDT test volume or revenue and shows growth in a later quarter.
Worry ifA later report gives no evidence of Prosigna LDT sales, or says its launch is delayed.
Why it matters: Veracyte plans a UroAmp test for patients after BCG treatment. The launch depends on development and coverage progress.
Watch forVeracyte reports development and reimbursement steps that keep the first UroAmp test on track for late 2028.
Also watch forVeracyte delays the planned late-2028 launch or reports a setback in test work or reimbursement.
Why it matters: Testing revenue grew 19% in Q2. Q3 results will show whether growth stays near the raised 2026 target.
Watch forQ3 testing revenue growth is at least 17% year over year, and 2026 guidance stays at $576 million to $582 million.
Also watch forQ3 testing revenue growth is below 17%, or Veracyte cuts its 2026 testing revenue range.
Why it matters: Medicare covers TrueMRD for muscle-invasive bladder cancer. Sales and more coverage would show whether the launch gains traction.
Supportive ifVeracyte reports more TrueMRD tests or higher revenue and keeps Medicare coverage.
Worry ifVeracyte reports no clear growth in TrueMRD use, or loses Medicare coverage.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$263 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $475 loss on $10,000 · 4.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,032 loss on $10,000 · 60.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.